Series A - Aro Biotherapeutics - 2021-01-05 - Crunchbase

Jan 5, 2021 · Aro Biotherapeutics raised $88000000 on 2021-01-05 in Series A. Northpond Ventures Northpond Ventures is a private equity and venture capital that focuses on science …

CouponFollow Extension

$88000000
OFF

Series A - Aro Biotherapeutics - 2021-01-05 - Crunchbase

3 weeks from now

Jan 5, 2021 · Aro Biotherapeutics raised $88000000 on 2021-01-05 in Series A. Northpond Ventures Northpond Ventures is a private equity and venture capital that focuses on science …

crunchbase.com

$88
OFF

Aro Biotherapeutics Secures $88M Series A - Vcnewsdaily.com

3 weeks from now

Aro Biotherapeutics Secures $88M Series A. Back to Home. 2021-01-05. Tweet. PHILADELPHIA, PA, Aro Biotherapeutics, a biotechnology company pioneering the development of tissue …

vcnewsdaily.com

$88
OFF

Philadelphia-based Aro Biotherapeutics Closes $88M Series A, …

3 weeks from now

Jan 5, 2021 · Aro Biotherapeutics founders Karyn O’Neil (left) and Sue Dillon. ... Jan 5, 2021 Aro Biotherapeutics ... Aro expects to use a portion of the Series A funds to "roughly double" in …

bizjournals.com

$88
OFF

Aro Raises Funds For RNA Delivery | C&EN Global Enterprise

3 weeks from now

Jan 11, 2021 · Aro Biotherapeutics has raised $88 million in series A financing to develop its method for delivering RNA therapies to specific cells. Founded in 2018 by Susan Dillon and …

acs.org

$88
OFF

Aro Biotherapeutics Hits $88m Series A Target

3 weeks from now

Jan 5, 2021 · Aro Biotherapeutics hits $88m series A target Jan 5, 2021 • Robert Lavine. ... JJDC were among the investors in a round that will fund development of Aro's centyrin-RNA …

globalventuring.com

$177
OFF

Aro Biotherapeutics - Raised $177M Funding From 8 Investors

3 weeks from now

Jan 23, 2025 · List of Aro Biotherapeutics's institutional investors. Johnson & Johnson Innovation, located in New Brunswick (United States), made their first investment in Aro Biotherapeutics …

tracxn.com

$41
OFF

Aro Biotherapeutics Secures $41.5M Series B Financing

3 weeks from now

Nov 28, 2023 · PHILADELPHIA--(BUSINESS WIRE)-- Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, …

biospace.com

$41500000
OFF

Series B - Aro Biotherapeutics - 2023-11-28 - Crunchbase

3 weeks from now

Nov 28, 2023 · Aro Biotherapeutics raised $41500000 on 2023-11-28 in Series B. Cowen Healthcare Investments Cowen Healthcare Investments is a financial services firm that …

crunchbase.com

$42000000
OFF

Series A - Soteria Biotherapeutics - 2021-05-17 - Crunchbase

3 weeks from now

May 17, 2021 · Soteria Biotherapeutics raised $42000000 on 2021-05-17 in Series A. Roche Venture Fund Roche Venture Fund makes investments in the development of commercially …

crunchbase.com

$41
OFF

Aro Biotherapeutics Secures $41.5M Series B Financing - ARO Live

3 weeks from now

Philadelphia, PA, November 28, 2023 --- Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced …

arobiotx.com

$24000000
OFF

Series B - Aro Biotherapeutics - 2022-12-12 - Crunchbase

3 weeks from now

Aro Biotherapeutics raised $24000000 on 2022-12-12 in Series B. Start Free Trial . Chrome Extension

crunchbase.com

$13717679
OFF

Series A - Aleta Biotherapeutics - 2021-07-16 - Crunchbase

3 weeks from now

Jul 16, 2021 · Aleta Biotherapeutics raised $13717679 on 2021-07-16 in Series A. Cookie Settings | Do Not Sell or Share My Personal Info

crunchbase.com

FAQs about Series A - Aro Biotherapeutics - 2021-01-05 - Crunchbase Coupon?

Who is Aro Biotherapeutics?

PHILADELPHIA-- ( BUSINESS WIRE )--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing. ...

When did Aro Biotherapeutics close?

Aro Biotherapeutics closed its last funding round on Nov 28, 2023 from a Series B round. Who are Aro Biotherapeutics's competitors? Alternatives and possible competitors to Aro Biotherapeutics may include Arvinas , Bicara Therapeutics , and Lassen Therapeutics. ...

How many investors does Aro Biotherapeutics have?

Aro Biotherapeutics has 10 investors including Cowen Healthcare Investments and Johnson & Johnson Innovation – JJDC. How much funding has Aro Biotherapeutics raised to date? Aro Biotherapeutics has raised . When was the last funding round for Aro Biotherapeutics? ...

What is Aro's new RNA therapy series a?

Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease. The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders. ...

What will Aro do with series a proceeds?

The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders. “ Aro is poised to deliver on the promise of our Centyrin platform to enable more efficient and precise delivery of RNA drugs to extra-hepatic tissues. ...

What are alternatives to Aro Biotherapeutics?

Alternatives and possible competitors to Aro Biotherapeutics may include Arvinas , Bicara Therapeutics , and Lassen Therapeutics. Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases. ...